



November 2006

Dear Participant:

The Board is very pleased that you will participate in its Face-to-Face meetings in November. The focus of our current consultations is to examine the Board's Excessive Price Guidelines, particularly with respect to the introductory patented drug price review, and to determine if they need to be amended to reflect today's pharmaceutical environment.

In preparation for the meeting, I encourage you to review the attached documents: agenda for the session, *PMPRB 101*, a summary of what we heard in response to the Discussion Guide and an issue summary on "re-benching". Additional information can be accessed on our Consultations Web page at <http://www.pmprb-cepmb.gc.ca/english/view.asp?x=647>, including the submissions made by stakeholders on the Discussion Guide. The *Participant's Kit* section will be of particular interest to you.

The Board is eager to learn more about your insights and perspectives as it considers the appropriateness of its current Guidelines. On behalf of my colleagues, I thank you for having accepted our invitation and look forward to an open and fruitful discussion.

Yours very truly,

Brien G. Benoit, M.D.
Chairperson